Market Expansion

Fort Lee – October 12, 2026 -- VUSSENS Inc., a wholly owned subsidiary of KOSDAQ-listed NEWEN AI, has set up its North American operations in New Jersey and launched its ontology-based AI beauty analytics platform in the U.S. market.

The company chose New Jersey for its proximity to New York, which it describes as a major global hub for international business and consumer goods distribution. It plans to draw on its local partnership network, including connections with New York University (NYU) Stern and the Global AI Frontier Lab in New York.

Platform runs on a language model trained on more than 800 billion tokens

The platform integrates cross-channel data from social media and e-commerce platforms in the U.S. market. A multimodal AI engine analyzes video, audio and subtitles at the same time across short-form content platforms such as YouTube and TikTok. This allows persona analysis by race, age, skin type and consumer values.

Norwich – October 12, 2026 -- Pikl, the insurance-backed revenue growth partner for the travel market, grew 7x between 2024 and 2025 and now covers about 20% of the UK short-term rental market, as its founder and CEO Louise Birritteri was named One to Watch in The LDC Top 50 Most Ambitious Business Leaders for 2026.

Pikl reports 2,024% premium growth from property managers in two years

Pikl reports gross written premium growth from property management companies (PMCs) of 2,024% from 2023 to 2025. The company says it has partnered with some of the largest enterprise PMCs globally. It also says partners have achieved revenue growth of up to 2.1x.

Taipei – October 12, 2026 -- China's National Medical Products Administration (NMPA) has approved CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for adult patients with advanced prostate cancer, Foresee Pharmaceuticals (TPEx: 6576) said. Licensing partner Changchun GeneScience Pharmaceutical (GenSci) notified Foresee of the approval of the Marketing Authorization Application and will commercialize the product in China.

GenSci holds exclusive China rights across all CAMCEVI indications

The license covers all current and pipeline indications: advanced prostate cancer, central precocious puberty (CPP) and premenopausal breast cancer. Foresee Chairman and CEO Ben Chien said GenSci's China launch will "significantly contribute" to the growth of the company's global CAMCEVI franchise.

Suwanee – October 12, 2026 -- Hisense will appoint James Fishler, a consumer electronics executive with more than 30 years of experience, as Chief Commercial Officer effective January 1, 2026, as the company expands its U.S. business.

Fishler brings Samsung, Beats, LG and Sony leadership experience to Hisense

Fishler previously served as chief executive over the TV, audio and memory business at Samsung Electronics America, where he led all sales and marketing across those categories. At Beats Electronics, later acquired by Apple, he oversaw worldwide go-to-market and channel marketing. He has also held leadership positions at LG and Sony Electronics.

His background spans B2C, B2B and D2C segments. According to Hisense, he has built cross-functional teams and retailer and distributor partnerships, and has worked on business planning, channel dynamics and new revenue streams in competitive categories.

San Carlos – October 12, 2026 -- Noah Medical has completed its first commercial procedure in Asia with the Galaxy System at Prince of Wales Hospital in Hong Kong, moving the robotic bronchoscopy platform from clinical study to routine hospital use in the region.

Hong Kong hospital moves Galaxy from clinical study to commercial use

The hospital performed the first clinical use of the platform in Asia in December 2023. The new procedure marks the transition from clinical investigation to commercial integration, according to the company.

Thoracic surgeon Dr. Calvin S. H. Ng, a Professor at the Chinese University of Hong Kong and Consultant Thoracic Surgeon at Prince of Wales Hospital, performed the procedure. Dr. Ng took part in early development of the Galaxy System, and the company says his input shaped its design.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.

Paris – October 09, 2026 -- GAC will debut the all-new AION UT Cross crossover, launch its global service brand and sign a strategic partnership with Chelsea Football Club at the 91st Paris Motor Show, running October 12 to 18 at Paris Expo Porte de Versailles.

GAC unveils Europe-specific crossover and localization strategy in Hall 5.1

The AION UT Cross is described by GAC as tailor-made for European mobility needs. The company will also present its in-depth localization strategy for Europe, covering products and services.

GAC will show models from its three portfolios: HYPTEC, GAC Motor and AION. The booth will also feature technologies including its energy ecosystem and smart green mobility.

Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.

Buyback plan allows cancellation or treasury retention of shares

Under the existing share repurchase mandate, repurchased shares may either be cancelled or held as treasury shares depending on future capital management needs. The plan will be executed subject to market conditions, with the Board stating it will balance business development priorities, strategic investment needs and financial flexibility.

First-half 2026 revenue climbs 3.6% to US$171.4 million

Sisram reported H1 2026 revenue of US$171.4 million, up 3.6% year-on-year. International markets excluding North America drove growth, rising 16.7% YoY to US$127.0 million, with APAC generating US$78.4 million, a 19.1% YoY increase.

Singapore – October 07, 2026 -- TOKEN2049, billed as the world's largest crypto conference, will launch its inaugural New York edition on 16-17 June 2027, expecting 15,000 attendees from around the world.

New York becomes TOKEN2049's third permanent flagship event

The announcement, made at TOKEN2049 Singapore, establishes New York as a permanent fixture on the conference's annual circuit alongside Singapore and Dubai. The expansion extends TOKEN2049's footprint across Asia, the Middle East and North America, placing the event at the center of global capital markets.

Citywide programme to accompany two-day main conference

Beyond the core two-day conference, TOKEN2049 Week will take over New York with a citywide programme of events and experiences, mirroring the format used in Singapore and Dubai.

Tickets priced at US$599 go on sale immediately

Tickets for TOKEN2049 New York are now on sale at US$599 per attendee.

Miami -- Wines of Chile will stage the first Miami edition of Chile Wine Fest on October 14, 2026, at the historic Alfred I. duPont Building, extending a trade event previously run twice in New York.

Twenty Chilean wineries confirm participation in Miami debut

Approximately 20 wineries from across Chile's growing regions will present premium portfolios, terroir-driven labels and heritage varieties during a trade session running from 1:00 p.m. to 4:00 p.m., followed by a consumer tasting from 6:00 p.m. to 8:00 p.m.

Julio Alonso, Executive Director of Wines of Chile USA, said Miami's strong Latin American ties and diversifying wine culture make it a strategic market for positioning Chile's producers and regions to trade buyers.